Medical Pipeline

Viscofan BioEngineering has collaborated very actively with academic entities in projects that have led to the development of new therapeutic strategies in various medical areas. We have currently two main research domains in our pipeline:

  • Regenerative therapies in which our collagen membranes are used in combination with cells to exert a therapeutic effect (as an ATMP)
  • Regenerative technologies in which our collagen alone or in combination with other materials is applied as a medical device.

The following pipeline depicts the development degree of the main projects of Viscofan BioEngineering.

medical pipeline.jpg


Cardiac repair

Ischemic cardiomyopathy is the leading cause of death in the developed world, representing 33% of deaths of patients above 35 years. Viscofan BioEngineering offers a unique opportunity to establish a new therapeutic system for cardiovascular treatment with a new regenerative therapy that could decrease adverse ventricular remodelling, main cause of cardiac failure in ischemic patients.
This project is based on the collaboration between Viscofan BioEngineering and the University Clinic of Navarra. Together we developed a new regenerative therapy based on the combination of adipose-derived stem cells (ADSC) seeded on CCC to promote the regeneration of damaged myocardial tissue (Publications).


Urethra repair

Around 300.000 patients suffer from urethra stricture every year and require an urethra substitute to recover normal urinary function.  The goal of this tissue engineering product is to replace urethral defects with artificial urothelium. A urothelial 3D tissue is established on the Collagen Cell Carrier (CCC) by using human urothelial cells.



We develop a new membrane with bovine origin for the use in dental applications.